Intelligent Nanotransducer for Deep-Tumor Hypoxia Modulation and Enhanced Dual-Photosensitizer Photodynamic Therapy
Youbin Li,Linman Du,Fei Li,Zhiming Deng,Songjun Zeng
DOI: https://doi.org/10.1021/acsami.1c24172
2022-03-23
Abstract:Upconversion nanoparticles (UCNPs) emerged as promising near-infrared (NIR) light-triggered nanotransducers for photodynamic therapy (PDT). However, the traditionally used 980 nm excitation source could cause an overheating effect on biological tissues, and the single photosensitizer (PS) loading could not efficiently utilize multiradiation UC luminescence, resulting in a limited efficiency of PDT in tumor tissues with hypoxia characteristics. Herein, 808 nm light-responsive Nd-sensitized 2@MnO2 core–shell NPs were designed as light nanotransducers with efficient UC emission at 550 and 650 nm for PDT and downshifting luminescence at 1525 nm for second NIR (NIR-II) imaging. UC emission was fully utilized by loading dual PSs, rose bengal (RB), and zinc phthalocyanine (ZnPc), thus significantly improving the reactive oxide species (ROS) generation efficiency. Moreover, a manganese dioxide (MnO2) shell with ultrasensitive biodegradability in an acidic tumor microenvironment (TME) can generate an amount of oxygen molecules, alleviating the symptoms of hypoxia and then improving the efficacy of PDT. Meanwhile, the biodegraded Mn2+ ions can further strengthen T1-weighted magnetic resonance imaging (MRI). This work presented a new multifunctional theranostic agent for combining NIR-II/MRI imaging and 808 nm light-triggered PDT to combat the limitations of cancer therapy.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsami.1c24172.Detailed methods, characterizations of the UCSM-RB/ZnPc nanoprobe, in vitro and in vivo NIR-II optical imaging, magnetic resonance imaging (MRI), in vitro cell compatibility and PDT (PDF)This article has not yet been cited by other publications.
materials science, multidisciplinary,nanoscience & nanotechnology